Aditxt (ADTX) Cost of Revenue (2021 - 2026)

Aditxt (ADTX) recorded quarterly Cost of Revenue of $9291.0 in Q1 2026, up 332.57% quarter-over-quarter from -$3995.0 in Q4 2025, and up 1165.8% on a YoY basis from $734.0 in Q1 2025.

Aditxt (ADTX) Cost of Revenue (2021 - 2026) Analysis & Trends

Aditxt's Cost of Revenue history runs 6 years deep, the most recent figure standing at $9291.0 for Q1 2026.

  • In Q1 2026, Cost of Revenue rose 1165.8% year-over-year to $9291.0; the TTM figure through Mar 2026 stood at $355059.0 (up 124.6% YoY), while the FY2025 annual figure was $401996.0, up 103.17% from the prior year.
  • Cost of Revenue was $9291.0 for Q1 2026 at Aditxt, up from -$3995.0 in the prior quarter.
  • In the past five years, Cost of Revenue ranged from a high of $833942.0 in Q2 2022 to a low of -$3995.0 in Q4 2025.
  • Historically, Cost of Revenue has averaged $144972.4 across 5 years, with a median of $103132.0 in 2024.
  • Biggest YoY gain for Cost of Revenue was 1341.2% in 2025; the steepest drop was 103.87% in 2025.
  • A 5-year view of Cost of Revenue shows it stood at $170166.0 in 2022, then soared by 67.99% to $285867.0 in 2023, then plunged by 63.92% to $103132.0 in 2024, then sank by 103.87% to -$3995.0 in 2025, then surged by 332.57% to $9291.0 in 2026.
  • The last three Cost of Revenue figures came in at $9291.0 (Q1 2026), -$3995.0 (Q4 2025), and $732.0 (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cost of Rev (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn - -
2 Belite Bio 58,560.00 Bn 58,560.00 Bn - -
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn - -
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn 64.20 Mn
5 Evaxion A 1,334.43 Bn 1,334.42 Bn - -
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn - -
7 Psyence Biomedical 212.16 Bn 212.16 Bn - 48,670.00
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn 392.80 Mn
9 Abivax 91.96 Bn 91.96 Bn - 2.05 Mn
10 Aditxt 2,485.68 -2.16 Mn 2,868.00 9,291.00

Historic Data

Download Data
DateValue
Mar 31, 2026 9,291.00
Mar 31, 2026 9,291.00
Dec 31, 2025 -3,995.00
Dec 31, 2025 -3,995.00
Sep 30, 2025 732.00
Sep 30, 2025 732.00
Jun 30, 2025 349,031.00
Jun 30, 2025 349,031.00
Mar 31, 2025 734.00
Mar 31, 2025 734.00
Dec 31, 2024 103,132.00
Dec 31, 2024 103,132.00
Sep 30, 2024 30,000.00
Sep 30, 2024 30,000.00
Jun 30, 2024 24,218.00
Jun 30, 2024 24,218.00
Mar 31, 2024 65,799.00
Mar 31, 2024 65,799.00
Dec 31, 2023 285,867.00
Dec 31, 2023 285,867.00